- $2.73bn
- $2.50bn
- $4.09m
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Ataibeckley Hart-Scott-Rodino Waiting Period For Eli Lilly Merger Expired August 28
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
AtaiBeckley Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. RESEARCH ROUNDUP- Anterix, Fidus Investment, Nextpower
U.S. RESEARCH ROUNDUP-IBM, MSCI, US Bancorp
Press Digest: British Business - July 17
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Citizens Financial, ManpowerGroup, Distribution Solutions
U.S. STOCKS ON THE MOVE-Citizens Financial, ManpowerGroup, Distribution Solutions
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Abbott, Citizens Financial, Lululemon Athletica
U.S. STOCKS ON THE MOVE-SpaceX, UnitedHealth, AtaiBeckley
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal (updated)
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer